1. Home
  2. Research
  3. Research Groups
  4. Neurodegenerative diseases: therapy development

Neurodegenerative diseases: therapy development

2023 Activity indicators

  • 8 competitive projects led: ISCIII, MICINN, CAM
  • 4 private led projects.
  • 10 competitive HR contracts.
  • 5 publications.
  • IF: 23.51
  • Q1 publications: 3 (60%)
  • D1 publications: 1 (20%)
  • 1 thesis
  • 3 awards awarded by UCM
  • Evaluators in national and European institutions: 3 PI
  • Members of editorial committees: 5 PI and 4 collaborators
  • 1 patent
  • 9 visitors received and 50 months' stay:
    • Universidad Complutense de Madrid
    • Universidad Autónoma de Madrid
    • Centro de Estudios Linkia FP
  • +8 months stay in foreign centres:
    • UCL Queen Square Institute of Neurology. London, United Kingdom 
    • Neurocentre Magendie Bordeaux Neurocampus. Bordeaux, France
    • VIB Center for Brain & Disease Research. KU Leuven. Leuven, Belgium

Milestones

  1. Alonso C, Satta V, Hernández I, Fernández J, Sagredo O. Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome. Neuropharmacology. 2023;237: 109602 - 109602. DOI:10.1016/j.neuropharm.2023.109602. PMID: 37290534.
  2. Santos I, Rodríguez C, Villegas P, Piscitelli F, Lauritano A, Shen CJ, Di V, Fernández J, de Lago E. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for  frontotemporal dementia using TDP-43 transgenic male mice. J. Neuroinflamm. 2023;20(1): 108 - 108. DOI:10.1186/s12974-023-02792-z. PMID: 37149645.
  3. Gómez M, Rodríguez C, Satta V, Hernández I, Navarro E, Fernández J. Endocannabinoid-Binding Receptors as Drug Targets. Methods Mol Biol. 2023:2576:67-94. DOI: 10.1007/978-1-0716-2728-0_6. PMID: 36152178.
  4. Arranque del proyecto de investigación: "MJFF-022552 Investigating GPR55 as a novel neuroprotective target in experimental Parkinson´s disease", financiado de manera competitiva por The Michael J. Fox Foundation (USA) y liderado por el Dr. Fernández Ruiz.
  5. Patent: WO2021/038219 "Use of cannabinoids in the treatment of dyskinesia associated with Parkinson´s disease" with national phase entry in the US (US 2023/0024312 AI)

Bibliometrics

  Articles ACCUM. FI MEAN IF ARTICLES Q1 OR Q2 % IN Q1 OR Q2 ARTICLES D1 % IN D1
2019 7 31.86 4.55 7 100 2 29
2020 6 29.85 4,98 6 100 1 17
2021 12 74.50 6.21 12 100 3 25
2022 5 27.33 5.47 5 100 0 0
2023 5 23.51 5.88 3 60 1 20
  35 187.05 5.42 33 94 7 20

* Sólo artículos originales, editoriales, guías y revisiones

Networks and alliances